The issue of patent eligibility has been a hotly litigated issue in the field of intellectual property law, and both the Federal Circuit and the Supreme Court have issued numerous decisions in recent years--particularly in the area of biotechnology. Attorneys Seth Northrop and Matt McFarlane discuss the impact that those decisions have had on the biotechnology industry and offer some tips for biotech firms looking to protect their intellectual property in the future.